[SCHEDULE 13D/A] BridgeBio Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

Amendment No. 8 to a Schedule 13D reports updated beneficial ownership information for the common stock of BridgeBio Pharma, Inc. ("Common Stock"). Multiple Viking-related entities and individuals are disclosed as reporting persons. Percentage calculations are based on 191,168,504 shares outstanding as of July 29, 2025. The cover pages show key positions: Viking Global Investors LP reports shared beneficial ownership of 17,780,183 shares (9.3%); Viking Global Opportunities-related entities report shared holdings of 17,489,651 shares (9.1%); and three individuals (O. Andreas Halvorsen, David C. Ott and Rose S. Shabet) are each reported with shared beneficial ownership of 18,602,920 shares (9.7%). The filing states the funds used were investor capital and incorporates a Schedule of Transactions as Exhibit 99.8. No transactions since Amendment No. 7 are reported except those listed in Exhibit 99.8.

Insights

Financial Analyst

TL;DR: Significant disclosed stakes by Viking-affiliated funds and principals approach 10%, a material ownership position to note.

The filing consolidates beneficial ownership across multiple Viking entities and identifies shared voting and dispositive power exercised through investment managers and general partners. Percentages are calculated on 191,168,504 outstanding shares, with key figures: 17,780,183 shares (9.3%) for Viking Global Investors LP and 18,602,920 shares (9.7%) for certain individuals. This scale of holdings is material for shareholder composition and could affect shareholder dynamics. The source of funds is investor capital and a transactions schedule is provided as Exhibit 99.8. The disclosure is procedural and updates prior Schedule 13D amendments without adding new narrative objectives.

Corporate Governance Expert

TL;DR: Clear mapping of voting/dispositive authority among funds, managers and named executives clarifies who may influence corporate votes.

The amendment details which entities have authority to vote and dispose of shares and describes how VGI, VGP, VLFGP, Opportunities Portfolio GP and related managers may be deemed beneficial owners through their control relationships. It also confirms delegated signing authority for filings. These disclosures improve transparency about which parties hold shared control over substantial positions, which is important for board engagement and voting outcomes. The filing references Exhibit 99.8 for transaction detail and incorporates prior amendments.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 8)

BridgeBio Pharma, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

10806X102

(CUSIP Number)

Matthew Bloom
General Counsel, 600 Washington Boulevard, Floor 11
Stamford, CT, 06901
(212) 672-7059

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/14/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

VIKING GLOBAL INVESTORS LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 17,780,183.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 17,780,183.00

11

Aggregate amount beneficially owned by each reporting person

17,780,183.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.3 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

All share percentage calculations in this Amendment No. 8 to the Schedule 13D are based on 191,168,504 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of July 29, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on August 5, 2025.

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

VIKING GLOBAL PERFORMANCE LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 213,000.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 213,000.00

11

Aggregate amount beneficially owned by each reporting person

213,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Equities II LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4,260.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4,260.00

11

Aggregate amount beneficially owned by each reporting person

4,260.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Equities Master Ltd.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 208,740.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 208,740.00

11

Aggregate amount beneficially owned by each reporting person

208,740.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Long Fund GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 77,532.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 77,532.00

11

Aggregate amount beneficially owned by each reporting person

77,532.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.04 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Long Fund Master Ltd.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 77,532.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 77,532.00

11

Aggregate amount beneficially owned by each reporting person

77,532.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.04 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Opportunities Parent GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 17,489,651.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 17,489,651.00

11

Aggregate amount beneficially owned by each reporting person

17,489,651.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Opportunities GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 17,489,651.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 17,489,651.00

11

Aggregate amount beneficially owned by each reporting person

17,489,651.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Opportunities Portfolio GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 17,489,651.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 17,489,651.00

11

Aggregate amount beneficially owned by each reporting person

17,489,651.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Opportunities Illiquid Investments Sub-Master LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 17,456,849.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 17,456,849.00

11

Aggregate amount beneficially owned by each reporting person

17,456,849.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.1 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Opportunities Liquid Portfolio Sub-Master LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 32,802.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 32,802.00

11

Aggregate amount beneficially owned by each reporting person

32,802.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.02 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

HALVORSEN OLE ANDREAS

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NORWAY

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 18,602,920.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 18,602,920.00

11

Aggregate amount beneficially owned by each reporting person

18,602,920.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.7 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Ott David C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 18,602,920.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 18,602,920.00

11

Aggregate amount beneficially owned by each reporting person

18,602,920.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.7 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Shabet Rose Sharon

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 18,602,920.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 18,602,920.00

11

Aggregate amount beneficially owned by each reporting person

18,602,920.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.7 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: BridgeBio Pharma, Inc.
(c)	Address of Issuer's Principal Executive Offices: 3160 Porter Drive, Suite 250, Palo Alto, CALIFORNIA , 94304.
Item 1 Comment: Pursuant to Rule 13d-2 under the Securities Exchange Act of 1934, as amended, this Amendment No. 8 to the Schedule 13D ("Amendment No. 8") amends certain items of the Schedule 13D filed with the Commission on July 8, 2019, as amended and supplemented by Amendment No. 1 filed with the Commission on July 19, 2023, Amendment No. 2 filed with the Commission on November 22, 2023, Amendment No. 3 filed with the Commission on August 20, 2024, Amendment No. 4 filed with the Commission on November 6, 2024, Amendment No. 5 filed with the Commission on January 31, 2025, Amendment No. 6 filed with the Commission on March 12, 2025 and Amendment No. 7 filed with the Commission on July 1, 2025 (collectively, the "Schedule 13D") relating to the Common Stock, par value $0.001 per share (the "Common Stock") of BridgeBio Pharma, Inc., a Delaware corporation (the "Issuer"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 of the Schedule 13D is hereby amended and supplemented as follows: The response to Item 5(c) of this Amendment No. 8 is incorporated by reference herein. The source of funds used in making the purchases is the capital invested in the Funds by their investors.
Item 4.	Purpose of Transaction
	Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The response to Item 5(c) of this Amendment No. 8 is incorporated by reference herein.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: The information contained on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 are hereby incorporated herein by reference. The percentage of outstanding shares of Common Stock that may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated for each Reporting Person based on 191,168,504 shares of Common Stock outstanding as of July 29, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Commission on August 5, 2025. VGEII has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, VGP, and by VGI, an affiliate of VGP, which provides managerial services to VGEII. VGEM has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its investment manager, VGP, and by VGI, an affiliate of VGP, which provides managerial services to VGEM. Viking Global Equities LP (a Delaware limited partnership) and Viking Global Equities III Ltd. (a Cayman Islands exempted company), through its investment in VGE III Portfolio Ltd. (a Cayman Islands exempted company), invest substantially all of their assets through VGEM. VLFM has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its investment manager, VLFGP, and by VGI, an affiliate of VLFGP, which provides managerial services to VLFM. Viking Long Fund LP (a Delaware limited partnership) and Viking Long Fund III Ltd. (a Cayman Islands exempted company), through its investment in Viking Long Fund Intermediate L.P. (a Cayman Islands limited partnership), invest substantially all of their assets through VLFM. Opportunities Fund has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to Opportunities Fund. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through Opportunities Fund. VGOL has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOL. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOL. VGI provides managerial services to the Funds. VGI has the power to direct the vote and disposition of the shares of Common Stock directly held by the Funds. Accordingly, VGI may be deemed to have beneficial ownership over any shares of Common Stock directly owned by the Funds. VGP serves as the general partner of VGEII and the investment manager to VGEM and has the power to direct the vote and disposition of the shares of Common Stock directly held by VGEII and VGEM. Accordingly, VGP may be deemed to have beneficial ownership over any shares of Common Stock directly owned by VGEII and VGEM. VLFGP serves as the investment manager of VLFM and has the power to direct the vote and disposition of the shares of Common Stock directly held by VLFM. Accordingly, VLFGP may be deemed to have beneficial ownership over any shares of Common Stock directly owned by VLFM. Opportunities Portfolio GP serves as the general partner of each of Opportunities Fund and VGOL and has the power to direct the vote and disposition of the shares of Common Stock directly held by Opportunities Fund and VGOL. Accordingly, Opportunities Portfolio GP may be deemed to have beneficial ownership over any shares of Common Stock directly owned by Opportunities Fund and VGOL. Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the power to direct the vote and disposition of the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by Opportunities Fund and VGOL. Accordingly, Opportunities GP may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by Opportunities Portfolio GP, consisting of any shares of Common Stock directly owned by Opportunities Fund and VGOL. Opportunities Parent serves as the sole member of Opportunities GP, which has the power to direct the vote and disposition of the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by Opportunities Fund and VGOL. Accordingly, Opportunities Parent may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by Opportunities GP, consisting of any shares of Common Stock directly owned by Opportunities Fund and VGOL. Messrs. Halvorsen and Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (the general partner of VGI), VGP, VLFGP and Opportunities Parent, have shared authority to direct the voting and disposition of the shares of Common Stock beneficially owned by VGI, VGP, VLFGP and Opportunities Parent. Accordingly, each of Messrs. Halvorsen and Ott and Ms. Shabet may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by VGI, VGP, VLFGP, Opportunities Parent and VGOL. Except as disclosed in this Amendment No. 8, none of the Reporting Persons beneficially owns any shares of Common Stock or has the right to acquire any shares of Common Stock. Except as disclosed in this Amendment No. 8, none of the Reporting Persons presently has the power to vote or to direct the vote or to dispose or direct the disposition of any shares of Common Stock that such Reporting Person may be deemed to beneficially own.
(b)	Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows: The information contained on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 are hereby incorporated herein by reference.
(c)	Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: Except for the transactions listed in Exhibit 99.8 of this Amendment No. 8, the Reporting Persons have not effected any transactions in the Common Stock since the filing of Amendment No. 7 on July 1, 2025.
Item 7.	Material to be Filed as Exhibits.
	Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 99.8 - Schedule of Transactions

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

VIKING GLOBAL INVESTORS LP

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
Date:	08/14/2025

VIKING GLOBAL PERFORMANCE LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of VIKING GLOBAL PERFORMANCE LLC (1)(2)(3)
Date:	08/14/2025

Viking Global Equities II LP

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Equities II LP (1)(2)(3)
Date:	08/14/2025

Viking Global Equities Master Ltd.

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Equities Master Ltd. (1)(2)(3)
Date:	08/14/2025

Viking Long Fund GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Long Fund GP LLC (1)(2)(3)
Date:	08/14/2025

Viking Long Fund Master Ltd.

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Long Fund Master Ltd. (1)(2)(3)
Date:	08/14/2025

Viking Global Opportunities Parent GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
Date:	08/14/2025

Viking Global Opportunities GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
Date:	08/14/2025

Viking Global Opportunities Portfolio GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
Date:	08/14/2025

Viking Global Opportunities Illiquid Investments Sub-Master LP

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
Date:	08/14/2025

Viking Global Opportunities Liquid Portfolio Sub-Master LP

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Liquid Portfolio Sub-Master LP (1)(2)(3)
Date:	08/14/2025

HALVORSEN OLE ANDREAS

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of HALVORSEN OLE ANDREAS (1)
Date:	08/14/2025

Ott David C.

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Ott David C. (2)
Date:	08/14/2025

Shabet Rose Sharon

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Shabet Rose Sharon (3)
Date:	08/14/2025

Comments accompanying signature:

(1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

FAQ

What stake in BridgeBio (BBIO) is reported by Viking Global Investors LP?

Viking Global Investors LP reports shared beneficial ownership of 17,780,183 shares, representing 9.3% of common stock based on 191,168,504 shares outstanding.

Which individuals are named as potentially having beneficial ownership?

The filing identifies O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet as Executive Committee members who may be deemed to have shared beneficial ownership of 18,602,920 shares (9.7%).

What source of funds was used for the reported purchases?

The source of funds for the purchases is stated as capital invested in the Funds by their investors.

Does the amendment report recent transactions in BridgeBio stock?

Except for transactions listed in Exhibit 99.8 to this Amendment No. 8, the Reporting Persons state they have not effected any transactions since Amendment No. 7 filed on July 1, 2025.

On what outstanding share count are the percentages based?

Percentages are calculated using 191,168,504 shares of common stock outstanding as of July 29, 2025.